Active Ingredient History
Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Soft Tissue Neoplasms (approved 2020)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Chordoma (Phase 2)
Colorectal Neoplasms (Phase 2)
COVID-19 (Phase 2)
Cytokine Release Syndrome (Phase 2)
Endometrial Neoplasms (Phase 2)
Ependymoma (Phase 2)
Glioma (Phase 2)
Hematologic Neoplasms (Phase 1)
Hepatoblastoma (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2)
Hodgkin Disease (Phase 2)
Hydrolases (Phase 2)
Kidney Diseases (Phase 2)
Liver Diseases (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 1/Phase 2)
Mesothelioma (Phase 2)
Mutation (Phase 2)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Nerve Sheath Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Rhabdoid Tumor (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Wilms Tumor (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue